Abstract: A disease diagnosing method and a disease diagnosing system are provided in the disclosure. The disease diagnosing method includes: obtaining continuous images of a body skin and generating a time domain signal according to an average pixel value of a region of interest in each frame of the continuous images; transforming the time domain signal to a frequency domain signal and combining the time domain signal and the frequency domain signal to a time frequency signal; retrieving multiple first features of a first high dimensional space of the time frequency signal to obtain multiple second features of a second high dimensional space; and use the second features as feature vectors to map to a high dimension feature space, and classifying the second features as one of the multiple categories of a disease corresponding to the region of interest in the body skin according to a hyperplane of the high dimension feature space.

Abstract: This disclosure is directed to an electronic device having a casing, a circular frame, and a display. A panel is arranged on one side of the casing, a circular opening is defined on the panel, and a first fixing structure is arranged on an inner edge of the circular opening. The circular frame is rotatably arranged in the circular opening to close the circular opening, a second fixing structure is arranged on an outer edge of the circular frame, and the second fixing structure is limited by the first fixing structure. The display is embedded in the circular frame and exposed on the panel, so that the display is rotatable according to various placing positions of the casing.

Abstract: A semiconductor device includes a substrate; a memory array over the substrate, the memory array including first magnetic tunnel junctions (MTJs), where the first MTJs are in a first dielectric layer over the substrate; and a resistor circuit over the substrate, the resistor circuit including second MTJs, where the second MTJs are in the first dielectric layer.

Abstract: A package structure including a photonic, an electronic die, an encapsulant and a waveguide is provided. The photonic die includes an optical coupler. The electronic die is electrically coupled to the photonic die. The encapsulant laterally encapsulates the photonic die and the electronic die. The waveguide is disposed over the encapsulant and includes an upper surface facing away from the encapsulant. The waveguide includes a first end portion and a second end portion, the first end portion is optically coupled to the optical coupler, and the second end portion has a groove on the upper surface.

Abstract: An integrated circuit package including electrically floating metal lines and a method of forming are provided. The integrated circuit package may include integrated circuit dies, an encapsulant around the integrated circuit dies, a redistribution structure on the encapsulant, a first electrically floating metal line disposed on the redistribution structure, a first electrical component connected to the redistribution structure, and an underfill between the first electrical component and the redistribution structure. A first opening in the underfill may expose a top surface of the first electrically floating metal line.

Abstract: A package includes a photonic layer on a substrate, the photonic layer including a silicon waveguide coupled to a grating coupler; an interconnect structure over the photonic layer; an electronic die and a first dielectric layer over the interconnect structure, where the electronic die is connected to the interconnect structure; a first substrate bonded to the electronic die and the first dielectric layer; a socket attached to a top surface of the first substrate; and a fiber holder coupled to the first substrate through the socket, where the fiber holder includes a prism that re-orients an optical path of an optical signal.

Abstract: An apparatus and method for visualization of process conditions in a process chamber or chambers, particularly during the fabrication of integrated circuits on substrates in the process chambers. The apparatus includes an inspection chamber which is installed adjacent to a process chamber. A camera provided in the inspection chamber is used to view the interior of the process chamber as the etching, chemical vapor deposition or other process is carried out in the process chamber. A video monitor is typically connected to the camera for viewing images from the camera. In the event that a defect-precipitating event occurs in the process chamber, such as a mechanical malfunction or accumulation of excessive levels of polymer deposition on the chamber walls, the event is displayed on the monitor in real-time.

Abstract: This invention directs to a method of assessing the concentration of an inhalational compound in the brain of a subject. The method includes administering a gas containing the compound into a subject to fill the pulmonary functional residual capacity, which is defined as the remaining lung volume at the end of an unforced respiration. The method also includes measuring an inspired compound concentration (Ci?) and an expired compound concentration (Ce?) after having filled the functional residual capacity with the gas. Therefore, a mixed venous compound concentration (Cb?) can be assessed based on the formula Cb?=[Ci?(M?1)+Ce?]/M, in which M is an alveolar membrane factor for the compound; and a brain compound concentration (Cb) can be assessed based on the formula Cb=(Ce?+Cb?)/2.

Abstract: This invention directs to a method of assessing the concentration of an inhalational compound in the brain of a subject. The method includes administering a gas containing the compound into a subject to fill the pulmonary functional residual capacity, which is defined as the remaining lung volume at the end of an unforced respiration. The method also includes measuring an inspired compound concentration (Ci?) and an expired compound concentration (Ce?) after having filled the functional residual capacity with the gas. Therefore, a mixed venous compound concentration (Cb?) can be assessed based on the formula Cb?=[Ci?(M?1)+Ce?]/M, in which M is an alveolar membrane factor for the compound; and a brain compound concentration (Cb) can be assessed based on the formula Cb=(Ce?+2Cb?)/3 or Cb=(Ce?+3Cb?)/4.

Abstract: An apparatus and method for visualization of process conditions in a process chamber or chambers, particularly during the fabrication of integrated circuits on substrates in the process chambers. The apparatus includes an inspection chamber which is installed adjacent to a process chamber. A camera provided in the inspection chamber is used to view the interior of the process chamber as the etching, chemical vapor deposition or other process is carried out in the process chamber. A video monitor is typically connected to the camera for viewing images from the camera. In the event that a defect-precipitating event occurs in the process chamber, such as a mechanical malfunction or accumulation of excessive levels of polymer deposition on the chamber walls, the event is displayed on the monitor in real-time.

Abstract: This invention directs to a method of assessing the concentration of an inhalational compound in the brain of a subject. The method includes administering a gas containing the compound into a subject to fill the pulmonary functional residual capacity, which is defined as the remaining lung volume at the end of an unforced respiration. The method also includes measuring an inspired compound concentration (Ci?) and an expired compound concentration (Ce?) after having filled the functional residual capacity with the gas. Therefore, a mixed venous compound concentration (Cb?) can be assessed based on the formula Cb?=[Ci?(M?1)+Ce?]/M, in which M is an alveolar membrane factor for the compound; and a brain compound concentration (Cb) can be assessed based on the formula Cb=(Ce?+2Cb?)/3 or Cb=(Ce?+3Cb?)/4.

Abstract: This invention directs to a method of assessing the concentration of an inhalational compound in the brain of a subject. The method includes administering a gas containing the compound into a subject to fill the pulmonary functional residual capacity, which is defined as the remaining lung volume at the end of an unforced respiration. The method also includes measuring an inspired compound concentration (Ci′) and an expired compound concentration (Ce′) after having filled the functional residual capacity with the gas. Therefore, a mixed venous compound concentration (Cb′) can be assessed based on the formula Cb′=[Ci′(M−1)+Ce′]/M, in which M is an alveolar membrane factor for the compound; and a brain compound concentration (Cb) can be assessed based on the formula Cb=(Ce′+Cb′)/2.

Abstract: This invention directs to a method of assessing the concentration of an inhalational compound in the brain of a subject. The method includes administering a gas containing the compound into a subject to fill the pulmonary functional residual capacity, which is defined as the remaining lung volume at the end of an unforced respiration. The method also includes measuring an inspired compound concentration (Cl′) and an expired compound concentration (Ce′) after having filled the functional residual capacity with the gas. Therefore, a mixed venous compound concentration (Cb′) can be assessed based on the formula Cb′=[Ci′(M−1)+Ce′]/M, in which M is an alveolar membrane factor for the compound; and a brain compound concentration (Cb) can be assessed based on the formula Cb=(Ce′+Cb′)/2.

Abstract: This invention directs to a method of assessing the concentration of an inhalational compound in the brain of a subject. The method includes administering a gas containing the compound into a subject to fill the pulmonary functional residual capacity, which is defined as the remaining lung volume at the end of an unforced respiration. The method also includes measuring an inspired compound concentration (Cl′) and an expired compound concentration (Ce′) after having filled the functional residual capacity with the gas. Therefore, a mixed venous compound concentration (Cb′) can be assessed based on the formula Cb′=[Ci′(M−1)+Ce′]/M, in which M is an alveolar membrane factor for the compound; and a brain compound concentration (Cb) can be assessed based on the formula Cb=(Ce′+Cb′)/2.

Abstract: An anesthetic applicator with a temperature/moisture regulating capability is provided. The anesthetic applicator includes: means for supplying anesthetic; an inner duct, connected to the anesthetic supplying means, for conducting the anesthetic to the patient; means for recycling the exhaled breath from the patent so that the recycled anesthetic can be resupplied via the inner duct to the patient; an outer duct sleeving the inner duct in such a manner that a passage is formed between the outer duct and the inner duct; and means for supplying a stream of heated fluid such as heated air or water to flow through the passage between the outer duct and the inner duct.

Abstract: The present invention relates to compounds containing dual substitutions of an aromatic amine and hindered phenol functionality useful as stabilizers for organic materials. These compounds are of the general formula: ##STR1## R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted aryl, and substituted or unsubstituted alkyl of 1 to 20 carbon atoms;R.sub.3 is alkylene of 1 to 10 carbon atoms;m is 0 or 1;n is an integer of 1 to 10;q is an integer of 0 to 8;z is 1 or 2, provided that, when q is 0, z must be 1;X represents the links of a chain q links in length, said links being selected from the group consisting of carbon, nitrogen, oxygen, sulfur, silicon, and mixtures thereof; andY is an aromatic group or .PHI., provided that Y can be .PHI.only when q is 0 and m is 1.

Abstract: Processes of preparing para substituted phenylamines, such as, p-phenylenediamines, and particularly, p-aminodiphenylamine. One process involves contacting phenylhydroxylamine with a nucleophilic reagent, such as aniline, in specified proportions and within a specified temperature range, in the absence of oxygen, and in the presence of a homogeneous acid catalyst, such as hydrochloric acid. A second process involves contacting phenylhydroxylamine with a nucleophilic reagent, such as aniline, in the presence of a solid acid catalyst, such as acidic zeolite Y, under reaction conditions.

Abstract: Processes of preparing para substituted phenylamines, such as, p-phenylenediamines, and particularly, p-aminodiphenylamine. One process involves contacting phenylhydroxylamine with a nucleophilic reagent, such as aniline, in specified proportions and within a specified temperature range, in the absence of oxygen, and in the presence of a homogeneous acid catalyst, such as hydrochloric acid. A second process involves contacting phenylhydroxylamine with a nucleophilic reagent, such as aniline, in the presence of a solid acid catalyst, such as acidic zeolite Y, under reaction conditions.

Abstract: Disclosed are mixed halocarbon blowing agents comprising (1) halocarbons boiling below about 10.degree. C., (2) halocarbons boiling between 20.degree. C. and 35.degree. C., and (3) inert organic liquids having a boiling point from about 35.degree. C. to about 125.degree. C.Also disclosed are blends of the above mixed blowing agents with active hydrogen containing compounds, particularly polyols and the rigid closed cell foams prepared from such blends.Up to 60 percent reduction in hard halocarbons is realized with the mixed blowing agents.

Abstract: A method is disclosed for removing certain contaminant phospholene and phospholane oxides or sulfides from organic fluid or fluid mixtures wherein the fluid or fluid mixture is contacted with a cation exchange resin insoluble in the mixture at a temperature of from about 20.degree. C. to about 100.degree. C.